Attendee search 

About HackensackUMC Mountainside Focused on medical excellence and community service for more than a century Patient focused, community oriented, conveniently located and equipped with technology that rivals the nation’s most prestigious healthcare systems, HackensackUMC Mountainside offers a comprehensive and growing array of services delivered by caring and highly skilled medical professionals. We’re proud of the therapeutic and administrative upgrades we have made. We’re the convenient, friendly community hospital that delivers the quality care, medical excellence and technology on which you can depend. HackensackUMC Mountainside has been serving Montclair and its surrounding New Jersey communities since 1891. The physicians, nurses and volunteers who are a part of the Mountainside family are also your friends and neighbors. We're your community, your hospital and your team, working hard on your behalf. Continuously moving forward Never content with the status quo, we continue to add services, staff, programs and technology to benefit our patients and our communities. From our state-of-the-art emergency center with its Fast Track program to our holistic mind-body women's program to our comprehensive cancer center and a weight-loss surgery program recognized nationally as a Center of Excellence, HackensackUMC Mountainside is the right choice in the greater Montclair area. In 1891, the beginning of a great tradition Margaret Jane Merewether Power was a preacher’s daughter who came from England to Montclair in 1874 with her husband. One summer day in 1890 she encountered a child who had fallen from a third-story window. Upset that there was no nearby healthcare facility where the child could be helped, she called on other women in her social circle to find a solution – marking the birth of HackensackUMC Mountainside. By 1891, a three-story cottage belonging to widow Eliza Sheridan had been purchased. Dr. John J.H. Love was named the first President of the Medical and Surgical Staff, and HackensackUMC Mountainside officially began its mission of “caring for, curing and nurturing the sick and injured.” Today, 119 years later, HackensackUMC Mountainside is still carrying out that mission. With 365 beds and 820,000 square feet in total, HackensackUMC Mountainside has come a long way. But some things never change. The compassion and commitment to the community felt by Mrs. Power continues to this day. A member of the Montclair Health Systems, LLC On February 1, Montclair Health System, LLC, a joint venture of LHP Hospital Group, Inc. and Hackensack University Medical Center, initiated the state government process required to acquire Mountainside Hospital.

HackensackUMC Mountainside is unique among New Jersey hospitals. While many others are seeking new owners because their futures remain uncertain, one of the nation’s most prestigious hospitals, HackensackUMC and LHP Hospital Group, Inc. one of the nation’s most innovative capital and healthcare management firms are choosing to affiliate with HackensackUMC Mountainside because of its strength and stability.

GLOBAL CARE Initiative is a French consortium of five non-profit Carnot research institutes dedicated to human health.

• CALYM, the Consortium for the acceleration of innovation and its transfer to the field of Lymphoma
• Curie Cancer, a component of Institut Curie focused on cancers
• ICM, the Brain and Spine Institute dedicated to CNS diseases
• Pasteur MI, the infectious diseases division of the Institut Pasteur
• Voir et Entendre, expert in vision and audition diseases and rehabilitation

Our goal is to operate as a one-stop shop to life sciences companies and research and technological organizations that seek effective R&D partnerships. The Carnot Institutes can collaborate at any stage — from basic research to late clinical phases. GLOBAL CARE Initiative combines strong scientific expertise to unique technology platforms to propose an innovation-centered collaboration offer.

Specialties

CNS Diseases, Vision and Audition Diseases, Cancers, Lymphoma, Infectious Diseases

GLOBAL CARE Initiative GLOBAL CARE Initiative is a consortium of 5 French leading research institutes focused on infectious diseases (The institut Pasteur), oncology (The institut Curie), lymphoma (CALYM), vision and audition diseases (Voir et Entendre) and CNS (The brain and spine institute). Industry sectors All Therapeutics Area CNS-Neurology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Oncology
Ophthalmology
Rare Disease
Your innovative solution

The institutes have joined to combine their efforts in fostering their international research partnerships with the industry and other RTOs.

Which problem are you solving ?

The consortium operates as a one-stop-shop for life science companies and research organizations that seek R&D collaboration from basic research to the late clinical phases

Target market segments

Basic research / Preclinical research / Clinical

Key value proposition

One stop shop for all of the insitutes / Translational research collaborations (biobanks-clinical data/trials - Epidemiologic data - Animal/cells models) / Access to European market (Patient population/Cormecial market/ European KOLs/clinical centers)/New sourcing for innovation

The Massachusetts Medical Device Development Center (M2D2) is a lifeline for the state’s smaller medical device companies, offering inventors and executives easy, affordable, and coordinated access to world-class researchers and resources at the Lowell and Worcester campuses of the University of Massachusetts.

Learn more.

We provide life cycle management solutions for innovator and branded pharmaceutical, medical device, biological products manufacturers. This entails winning difficult-to-obtain patents, designing Intellectual Property strategy and enforcing intellectual property to maintain market share.

I will shortly begin to interview companies able to register and launch a new US Rx product outside the US.  Partner companies must have (a) a women's health or rheumatology sales force; (b) experience registering hormone products; and (c) the ability to move quickly. 

From helping Tenet Healthcare stave off a hostile takeover to obtaining summary judgment for a former health care general counsel in a precedent-setting False Claims Act case to establishing ERISA preemption precedent in the United States Supreme Court on behalf of Aetna, achieving successful outcomes for our clients in their most important matters is our singular focus.

Protecsom 

ProtecSom designs smart respiratory drug delivery devices to improve pulmonary drug distribution and patients life.

Industry sectors Medtech Therapeutics Area Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Your innovative solution

Optim'Hal provides real-time information on the drug dose inhaled from a metered dose inhaler with a spacer device. It sends this information to any computer, smartphone or tablet and also converts it as light and sound signals to encourage drug taking among toddlers.

Which problem are you solving ?

Compliance is a major problem with asthma sufferers. Thanks to incentive provided to patients, children and parents, Optim'Hal improves compliance. The inhaled dose and speed of the inspiratory flow are critical to the reliability of the inhaled treatment. Thanks to information about these settings, Optim'Hal' makes the treatment more reliable.

Target market segments

Asthma and COPD sufferers. /Any inhaled treatment. /Research centers about aerosoltherapy.

Key value proposition

Better compliance, thanks to incentive signals or applications depending on the age / Better surveillance, thanks to true data on patient compliance available for caregivers / Improving pulmonary drug distribution thanks to information on inspiratory flow

Company Overview

Provid Pharmaceuticals Inc. was founded to discover novel therapeutics for autoimmune diseases using peptide mimetics technology.   Provid’s strategy has resulted in the discovery of PV-267, a small molecule drug candidate for the treatment of multiple sclerosis (MS) and leads for rheumatoid arthritis and other autoimmune diseases that operate by blocking disease-associated MHC class II molecules.

Provid’s MS drug candidate, PV-267 uniquely inhibits the MHC Class II molecule HLA-DR2b, the most important gene target in the autoimmune disease process in MS.  MS is genetically linked with HLA-DR2b (DRB1*1501).  DR2b is carried by a majority of MS patients (ca. 700,000 worldwide) and binds and presents antigenic myelin fragments to autoreactive T cells, triggering the autoimmune response that damages myelin insulation on nerves, leading to MS disease symptoms and disability.  Provid designed PV-267 to bind tightly and selectively to DR2b, blocking antigen binding.  PV-267 has been shown to disrupt the autoimmune process in MS animal models and in human cells from DR2+ patients.  Because PV-267 does not compromise other aspects of the immune system, its potential for superior safety is a major advantage over current disease-modifying drugs.

Recent data have shown that PV-267 has high oral bioavailability in a proprietary formulation being developed in collaboration with Enteris Biopharma.  Oral efficacy, while not essential to test the concept of the DR2 inhibitory mechanism, is an important factor commercially and for the MS patient.

Early Clinical Trial Concept.  Because of its DR2b antagonist mechanism, it is feasible to assess immunological efficacy in DR2b+ individuals in early clinical trials, greatly reducing the clinical development risk and clearing the path for a targeted phase II efficacy trial.  These studies are being planned by our Clinical Advisory Board under the leadership of Prof. Larry Steinman at Stanford. 

Development Plan. Provid will pursue preclinical and early clinical studies of our DR2b inhibitors and is seeking partnerships with pharma company partners.